Withdrawn × Myelodysplastic Syndromes × Clear all
NCT05201183 2023-12-11

A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies

Indiana University

Phase 1/2 Withdrawn
NCT00816413 2023-08-14

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

University of Nebraska

Phase 1/2 Withdrawn
NCT00900120 2021-09-21

Collecting and Storing Blood Samples From Patients With Cancer

Rutgers, The State University of New Jersey

Withdrawn
NCT03602898 2021-06-30

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Withdrawn
NCT03807063 2020-08-14

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 1 Withdrawn
NCT00004114 2020-07-31

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
NCT00085449 2019-11-27

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
NCT02118311 2017-12-02

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
NCT00770419 2015-05-29

Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers

Rutgers, The State University of New Jersey

Withdrawn
NCT00081055 2014-12-04

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Mesoblast, Ltd.

Phase 2 Withdrawn